Anixa Biosciences Inc Dossier
Qualitative Analysis
Business overview
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company's therapeutic portfolio is anchored by an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing a novel chimeric endocrine receptor-T cell (CER-T) technology. This technology is highly differentiated from traditional cell therapies as it uses the natural follicle-stimulating hormone (FSH) ligand to bind to the FSHR receptor on tumor cells rather than relying on antibody fragments. Additionally, Anixa is developing a pipeline of cancer vaccines in collaboration with the Cleveland Clinic. These vaccines target "retired" proteins—proteins that are expressed during specific physiological states (such as lactation) but are otherwise absent from normal adult tissues, yet aberrantly expressed in certain cancers. The lead vaccine candidate is an investigational breast cancer vaccine targeting alpha-lactalbumin, initially focused on triple-negative breast cancer (TNBC).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the breast cancer vaccine targeting alpha-lactalbumin (developed in collaboration with Cleveland Clinic) into a Phase 2 clinical trial following positive Phase 1 results that demonstrated safety, tolerability, and immune responses in 74% of participants.
Expected impact: Establish clinical proof-of-concept for a prophylactic vaccine designed to prevent triple-negative breast cancer, opening up a massive global market.
Developing a novel follicle-stimulating hormone receptor (FSHR)-targeted CAR-T therapy, known as chimeric endocrine receptor-T cell (CER-T) technology, for the treatment of recurrent ovarian cancer in partnership with Moffitt Cancer Center.
Expected impact: Provide a highly differentiated cell therapy that targets the FSHR receptor on tumor cells using natural ligands, potentially extending survival in heavily pretreated ovarian cancer patients.
Securing international patent protections for its cancer vaccine and CAR-T technologies in key global markets.
Expected impact: Strengthens the company's international patent estate, enhancing its leverage to pursue global commercialization and licensing partnerships with major pharmaceutical companies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. Cleveland Clinic is the birthplace of Anixa's breast and ovarian cancer vaccine technologies. Anixa holds exclusive licenses to these technologies, while Cleveland Clinic is entitled to royalties and commercialization revenues.
Terms: Exclusive licensing agreement with royalty and commercialization revenue-sharing terms.
High. Moffitt Cancer Center conducts the clinical trials and co-develops Anixa's novel FSHR-targeted CAR-T therapy (liraltagene autoleucel) for recurrent ovarian cancer.
Terms: Collaborative clinical development agreement.
Medium. Cytovance will provide cGMP manufacturing solutions to produce clinical materials for Anixa's planned Phase 2 breast cancer vaccine trial.
Terms: Contract manufacturing services agreement.